Literature DB >> 29552355

Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin.

Yuki Matsumoto1, Mario Tsuchiya1, Shakespear Norshalena1, Chikako Kaneko1, Jin Kubo1, Teiji Yamamoto1, Toshiyuki Takahashi2,3, Kazuo Fujihara4,3.   

Abstract

A 26-year-old, 17-week pregnant woman developed aquaporin-4-IgG-positive severe longitudinally extensive transverse myelitis during the course of disseminated herpes zoster and became quadriparetic. She was unresponsive to high-dose intravenous methylprednisolone but became able to walk without assistance after intravenous immunoglobulin. One and a half months later, left optic neuritis developed but her vision improved with intravenous immunoglobulin. The only sequela was left T5 girdle sensation, and she delivered a healthy baby. Intravenous immunoglobulin may be a rescue therapy in aquaporin-4-IgG-positive neuromyelitis optica attacks in pregnant women, especially those with severe infections.

Entities:  

Keywords:  Neuromyelitis optica; acute treatment; aquaporin-4-IgG; herpes zoster; intravenous immunoglobulin; pregnancy

Year:  2018        PMID: 29552355      PMCID: PMC5846931          DOI: 10.1177/2055217318758119

Source DB:  PubMed          Journal:  Mult Scler J Exp Transl Clin        ISSN: 2055-2173


Introduction

Aquaporin-4 (AQP4)-antibody-seropositive neuromyelitis optica (NMO) often affects women in their childbearing years. There have been only a few reports of acute-phase treatment in pregnant patients with seropositive NMO. [1] In relapses of seropositive NMO, the first-line therapy is intravenous methylprednisolone (IVMP), and plasma exchange (PLEX) is a rescue therapy in those unresponsive to IVMP.[1] There are also several reports suggesting therapeutic efficacy of intravenous immunoglobulin (IVIg) in acute-phase NMO,[2-7] but there are no reports of pregnant patients with seropositive NMO treated with IVIg as a rescue therapy. Here we describe a pregnant woman who developed seropositive NMO following disseminated herpes zoster. She was refractory to IVMP but successfully treated with IVIg. We obtained the patient’s written consent and the institutional review board’s approval for publication.

Case report

The patient was a 26-year-old pregnant woman (gravida 3 partus 2). In May 2016, the patient felt burning pain over her neck, both arms and anterior chest. One week later, she had vesicular skin lesions with crusts and erosions suggestive of varicella zoster infection in those areas. After two more weeks, she had left hemiparesis that then progressed to quadriparesis. In her 17th week of pregnancy, the patient was referred to our hospital by a local obstetrician. On admission, the patient was bedridden and could not even sit up. She had a high fever (38.8°C) and severe tingling pain below the neck level aggravated by minor stimuli, which was compatible with allodynia. She also had constipation lasting a week. Physical examination revealed oral candidiasis and vesicles accompanied by crusts and erosions over her right C4, bilateral C5–6 and left Th3 areas. Neurological examination showed profound quadriparesis (manual muscle strength of Medical Research Council 3/5 over the arms and 2/5 over the legs), generalized hyperreflexia, severe hypoesthesia in legs and bowel-bladder disturbance. Varicella-zoster virus (VZV) polymerase chain reaction and VZV-immunoglobulin M (IgM) were negative in the cerebrospinal fluid collected at the onset of myelitis. The patient also had hyponatremia (120 mEq/l) that was asymptomatic and resolved on day 8. Brain and spinal magnetic resonance imaging (MRI) revealed a left hypothalamic T2-hyperintense lesion and a longitudinally extensive transverse lesion extending from the lower medulla down to Th6 (Figure 1). However, she did not have dyspnea, hiccups or nausea/vomiting. The patient was treated with acyclovir (1500 mg/day) and heparin.
Figure 1.

(a) Spinal magnetic resonance imaging on day 2 exhibited a T2-hyperintense lesion extending from the medulla oblongata to the thoracic cord. (b) Axial image at the C1 level revealed an extensive lesion, mainly involving the central gray matter. (c) Axial image at the midbrain level showed a left hypothalamic lesion. (a) and (b): T2-weighted images. (c): Fluid-attenuated inversion recovery image.

(a) Spinal magnetic resonance imaging on day 2 exhibited a T2-hyperintense lesion extending from the medulla oblongata to the thoracic cord. (b) Axial image at the C1 level revealed an extensive lesion, mainly involving the central gray matter. (c) Axial image at the midbrain level showed a left hypothalamic lesion. (a) and (b): T2-weighted images. (c): Fluid-attenuated inversion recovery image. We suspected NMO at that point, and administered intravenous methylprednisolone (IVMP) (1 g/day for five days) on the day of admission. However, her symptoms deteriorated and she became completely paraplegic. Then, we treated her with intravenous immunoglobulin (IVIg) (0.4 mg/kg/day) rather than plasma exchange (PLEX) because of risks of suspected sepsis and circulatory instability affecting the fetus. After IVIg was given on days 6 and 7, she developed a headache, and thus we discontinued the therapy. Although she barely moved her toes on day 7, she became able to raise her right knee on day 10. On day 13, serum AQP4-immunoglobulin G (IgG)) was found to be strongly positive (titers > 75 U/ml), thus fulfilling the diagnostic criteria of NMO with AQP4-IgG.[8] The patient could not even brush her teeth on day 6 but was able to eat her meals without assistance on day 13. Then she received additional doses of IVIg from day 15 to day 17 with no side effects. Following this, she became able to raise her knees on day 16, dorsiflex her ankles on day 17 and stand up with assistance on day 21. She was given IVIg again from day 25 to day 29 and was able to walk with a walker on day 33. She needed laxatives and disimpaction for constipation and placement of an indwelling urinary catheter for urinary retention until day 29. But urinary and bowel symptoms improved thereafter and herpes zoster was epithelialized and scarred by day 33. On day 41, she noticed left orbital pain and blurred vision. Her left visual acuity was 20/200 and upper altitudinal hemianopia was observed, indicating the development of left optic neuritis. Then, IVMP (1 g/day for five days) was given but she was refractory to it (20/400 in one week). She was then treated with the same doses of IVIg again but it had to be discontinued because of vomiting two days later. When she was discharged on day 70, she was able to read the headlines of a newspaper with remaining girdle sensation over the left T5 level. A month later, the patient gave birth at 37 weeks’ gestation to a baby without any complications via spontaneous vaginal delivery. Her visual acuity gradually returned to normal although she still had the left T5 girdle sensation.

Discussion

Rescue therapy for severe NMO attacks refractory to IVMP in pregnant women with concomitant infections is not well established. There have been two cases of acute exacerbations of NMO in pregnancy that failed to respond to IVMP but were successfully treated with PLEX (Table 1 (a)).[1,9] In our patient with corticosteroid-resistant NMO attacks, we chose IVIg rather than PLEX on the assumption that IVIg might also be effective for infections (disseminated herpes zoster, candidiasis and possible sepsis) as well as NMO. In fact, cases of infectious or parainfectious NMO/longitudinally extensive transverse myelitis (LETM) (mostly associated with herpes zoster) have been reported (Jarius S, et al. J Neurol Sci. 2009) and there are some reports on safety and efficacy of IVIG in immune-mediated diseases with concomitant infections (Simoes J, et al. J Clin Rheumatol. 2015).[10,11] Possible mechanisms of IVIG efficacy in NMO spectrum disorder may include modulations of AQP4-IgG binding and catabolism, complement activation and B-cell function (Wingerchuk DM. J Clin Immunol 2013). Moreover, IVIg is unlikely to cause circulatory instability adversely affecting the fetus, in contrast to PLEX. Despite short-term IVIg administrations because of adverse effects, the patient experienced significant neurological improvement of LETM while the improvement of optic neuritis was slower. IVIg has also been reported to be safe in neuroimmunological disorders such as myasthenia gravis and pregnancy.[12]
Table 1.

(a) Case reports of therapeutic plasma exchange in AQP4-IgG-positive NMO during pregnancy and (b) case reports of intravenous immunoglobulin therapies in acute phase of AQP4-IgG-positive NMO.

Table 1 (a) Age (gestation weeks) Onset or relapse Clinical symptoms and MRI findings Acute treatment before PLEX Times of PLEX Effects of PLEX Reference
Case 125 (17)RelapseRespiratory failure, cervical and thoracic LETMCorticosteroids (unknown details)Four timesComplete recoveryCornelio 2009
Case 227 (20)RelapseParaplegia, cervical and thoracic LETMIVMPFive timesPartial recoveryRubio Tabares 2016
Table 1 (b) Age, sex Onset or relapse Clinical symptoms and MRI findings Acute treatment before IVIg IVIg Effects of IVIg Reference
Case 349, FOnsetGait disturbance, myelitis from Th4 to Th6IVMP0.4 g/kg per day over five daysComplete recoveryIi 2008
Case 481, MOnsetParaplegia, myelitis from Th5 to Th11IVMPUnknownComplete recoveryNakano 2009
RelapseRespiratory failure, LETM from medulla oblongata to C6IVMP and IVIgUnknownNo improvementNakano 2009
Case 532, FOnsetCognitive impairment, periventricular white matter lesionsIVMP0.4 g/kg per day over five daysPartial recoveryStübgen 2012
Case 637, MOnsetCognitive impairment, periventricular white matter lesionsIVMP0.4 g/kg per day over five daysPartial recoveryStübgen 2012
Case 728, FRelapseONIVMPUnknownPartial recoveryRomanelli 2014
Case 866, FOnsetON and myelitisCorticoids (unknown details)UnknownComplete recoveryHervás-García 2014
Case 943, FRelapseRespiratory failure, cervical myelitisNone2 g/kg per day over five daysPartial recoveryElsone 2014
Case 1038, FRelapseBilateral ONPLEX, oral PSL2 g/kg per day over five daysNo improvementElsone 2014
Case 1149, FRelapseParaplegia, thoracic LETMIVMP2 g/kg per day over five daysNo improvementElsone 2014
Case 1240, FRelapseTetraplegia and heart failure, cervical LETMIVMP followed by oral PSL2 g/kg per day over five daysPartial recoveryElsone 2014
Case 1379, FRelapseTetraplegia, cervical LETMIVMP followed by oral PSL2 g/kg per day over five daysNo improvementElsone 2014
Case 1457, MRelapseTetraplegia, cervical and thoracic LETMIVMP2 g/kg per day over five daysImproved to baseline functionElsone 2014
Case 1538, FRelapseTetraplegia, cervical LETMIVMP, PLEX followed by oral PSL2 g/kg per day over five daysImproved to baseline functionElsone 2014
Case 1655, MRelapseBilateral ONOral PSL2 g/kg per day over five daysNo improvementElsone 2014

AQP4: aquaporin 4; F: female; IgG: immunoglobulin G; IVIg: intravenous immunoglobulin; IVMP: intravenous methylprednisolone; LETM: longitudinally extensive transverse myelitis; ON: optic neuritis; M: male; MRI: magnetic resonance imaging; NMO: neuromyelitis optica; PLEX: plasma exchange; PSL: prednisolone.

(a) Case reports of therapeutic plasma exchange in AQP4-IgG-positive NMO during pregnancy and (b) case reports of intravenous immunoglobulin therapies in acute phase of AQP4-IgG-positive NMO. AQP4: aquaporin 4; F: female; IgG: immunoglobulin G; IVIg: intravenous immunoglobulin; IVMP: intravenous methylprednisolone; LETM: longitudinally extensive transverse myelitis; ON: optic neuritis; M: male; MRI: magnetic resonance imaging; NMO: neuromyelitis optica; PLEX: plasma exchange; PSL: prednisolone. In NMO, 14 cases (15 attacks) treated with IVIg as a rescue therapy have been reported in the literature and IVIg was efficacious in 10 attacks (Table 1 (b)).[2-7] The main reason why IVIg was administered in those cases was unresponsiveness to IVMP or PLEX. In some patients unresponsive to IVIg, the median time from relapse to IVIg was longer than the intervals in those who responded to IVIg (3.5 months vs a week), suggesting early institution of IVIg is associated with better outcomes.[7] Owing to clinical deterioration during IVMP, IVIg was started without delay in our patient, which probably contributed to a favorable therapeutic response although a delayed effect of IVMP cannot be completely ruled out. Given that many women with seropositive NMO are of childbearing age, IVIg may be useful as rescue therapy in AQP4-IgG-positive NMO attacks refractory to IVMP in pregnant patients, especially when complicated with infectious diseases.
  12 in total

1.  Devic's neuromyelitis optica and pregnancy: distinction from multiple sclerosis is essential.

Authors:  Daniela Baumann Cornelio; Regina Pedrini Braga; Marcos Wengrover Rosa; Antônio Celso Ayub
Journal:  Arch Gynecol Obstet       Date:  2009-01-17       Impact factor: 2.344

2.  Use of intravenous immunoglobulin in patients with active vasculitis associated with concomitant infection.

Authors:  Joana Simoes; Savino Sciascia; Ines Camara; Simone Baldovino; Yousuf Karim; Dario Roccatello; Maria Jose Cuadrado
Journal:  J Clin Rheumatol       Date:  2015-01       Impact factor: 3.517

Review 3.  Neuromyelitis optica: potential roles for intravenous immunoglobulin.

Authors:  Dean M Wingerchuk
Journal:  J Clin Immunol       Date:  2012-09-14       Impact factor: 8.317

4.  [Senile-onset recurrent myelitis with anti-aquaporin-4 antibody].

Authors:  Yukihito Nakano; Katsuichi Miyamoto; Yohei Inatsugi; Hidekazu Suzuki; Susumu Kusunoki
Journal:  Brain Nerve       Date:  2009-05

5.  Reversible stenosis of large cerebral arteries in a patient with combined Sjögren's syndrome and neuromyelitis optica spectrum disorder.

Authors:  Yuichiro Ii; Akihiro Shindo; Ryogen Sasaki; Yutaka Naito; Keiko Tanaka; Shigeki Kuzuhara
Journal:  Rheumatol Int       Date:  2008-05-21       Impact factor: 2.631

6.  Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.

Authors:  Liene Elsone; Jay Panicker; Kerry Mutch; Mike Boggild; Richard Appleton; Anu Jacob
Journal:  Mult Scler       Date:  2013-08-28       Impact factor: 6.312

Review 7.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

8.  [Encephalopathy and neuromyelitis optica: the importance of recognising atypical symptoms].

Authors:  José V Hervás-García; Laia Grau-López; Sira Doménech-Puigcerver; Cristina Ramo-Tello
Journal:  Rev Neurol       Date:  2014-01-01       Impact factor: 0.870

Review 9.  Plasma exchange therapy for a severe relapse of Devic's disease in a pregnant woman: A case report and concise review.

Authors:  Jonathan Rubio Tabares; Pablo Felipe Amaya Gonzalez
Journal:  Clin Neurol Neurosurg       Date:  2016-07-04       Impact factor: 1.876

Review 10.  International consensus guidance for management of myasthenia gravis: Executive summary.

Authors:  Donald B Sanders; Gil I Wolfe; Michael Benatar; Amelia Evoli; Nils E Gilhus; Isabel Illa; Nancy Kuntz; Janice M Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David P Richman; Jan Verschuuren; Pushpa Narayanaswami
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.